Fate Therapeutics' IPO

Fate Therapeutics raised a round of funding on October 01, 2013. Investors include Public.

Fate Therapeutics (NASDAQ: FATE) is a biotechnology company developing stem cell modulators (SCMs), biologic or small molecule compounds that guide cell fate, to treat patients with very few therapeut…

Articles about Fate Therapeutics' IPO: